CompletedPhase 1NCT00077558
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Studying Acute basophilic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Principal Investigator
- Judith E. Karp, MDSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Intervention
- fludarabine phosphate(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2004
Study locations (4)
- Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
- Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
- M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00077558 on ClinicalTrials.govOther trials for Acute basophilic leukemia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT01627041Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid LeukemiaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT00898456Multidrug Resistance Genes in Patients With Acute Myeloid LeukemiaAlliance for Clinical Trials in Oncology